Marvin Zelkowitz
Flossmoor, ILNPI 1730189259
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,001 and has fallen 94.0% since, to $60 in 2023.
Across 54 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$215
- Novartis$144
- EMD Serono, Inc.$92
- Amgen$81
- Sanofi$70
- Lundbeck LLC$67
- plus $417 from 12 others
Across 39 payments — averaging $28,347 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.1M
- EMD Serono, Inc.$10K
What the payments were for
- Speaking & faculty fees$121%
- Food & beverage$1,07299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 8 | $215 |
| Novartis | 9 | $144 |
| EMD Serono, Inc. | 6 | $92 |
| Amgen | 3 | $81 |
| Sanofi | 3 | $70 |
| Lundbeck LLC | 4 | $67 |
| AstraZeneca | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $60 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
| Genentech USA, Inc. | 3 | $51 |
| Pfizer | 2 | $41 |
| Vertical Pharmaceuticals, LLC | 2 | $32 |
| Akcea Therapeutics, Inc. | 1 | $24 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| Bayer | 1 | $23 |
| Strongbridge US Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Acorda Therapeutics, Inc | 1 | $12 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.